Walvax Biotechnology’s RQ3013 mRNA Vaccine Shows Efficacy in Phase III Study
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the efficacy interim results of a...
SHE: 300142
Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy...
AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...
Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with...
Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb...
Walvax Biotech Enrolls First Subject in Phase III HPV Vaccine Study
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced the first subject enrollment for a Phase...
Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National...
Walvax’s mRNA Vaccine AWcorna Shows Superior Immune Response in Phase III Trial
Walvax Biotechnology Co., Ltd’s (SHE: 300142) mRNA vaccine against SARS-CoV-2, named AWcorna, has reached the...
Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...